FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281501> ?p ?o ?g. }

• W4379281501 endingPage "7036" @default.
• W4379281501 startingPage "7036" @default.
• W4379281501 abstract "7036 Background: Ivosidenib (IVO) twas approved based on a CR/CRh rate of 31.8% in IDH1 mutant (IDH1m) R/R AML; median duration of CR/CRh (DOR) was 8.2 months (mo). The purpose of this study is to elucidate the clinical and molecular characteristics of exceptional responders to single agent IVO. Methods: We analyzed all patients (pts) with IDH1m R/R AML who received IVO 500mg QD on the phase 1 dose escalation/expansion study and had a DOR of >12 mo. Results: Of 179 pts who received IVO 500 mg QD, 57 (31.8%) achieved a CR/CRh. Of these, 20 (35.1%) had a DOR >12 mo. After excluding 7 pts who went to HSCT, 13 (22.8% of responders, 7.3% of cohort) had DOR >12 mo (exceptional response) and 8 (14% of responders, 4.5% of cohort) had DOR >24 mo. The 13 exceptional responders all achieved CR as best response, and median DOR was 42.6 mo. Median OS was not reached; estimated OS at 48 mo was 67.1%. Median EFS was 44.4 mo. Reasons for discontinuing treatment included relapse (n=4), adverse event unrelated to IVO (n=3), and patient (pt) decision (n=3). Three pts remain on treatment. All pts who relapsed had DOR between 1-2 years; none of the 8 pts with DOR >2 years relapsed. Baseline characteristics are in the table. The most common co-mutations were DNMT3A, ASXL1, SRSF2, and JAK2 (3 each, 23%). Five pts (39%) had a splicing factor mutation. No pts had FLT3 or RTK pathway mutations other than JAK2. Only 1 pt with NPM1 had an exceptional response, and 1 pt had TP53 (VAF 3.6%). Six pts (46%) had an abnormal karyotype, 6 normal (46%), and 1 missing (8%). Most pts had intermediate-risk cytogenetics (10 pts, 77%), 2 poor-risk, and 1 missing. The median IDH1 VAF was 25% (range 10-50%). The median number of co-mutations was 1 (range 0-6). Having 0-1 co-mutations was associated with a longer response. Eleven pts (85%) had an IDH1 R132C mutation; 1 each (7.7%) had R132H and R132L mutations. Mutation clearance of IDH1 was noted in 8 pts (61.5%). Conclusions: A subset of pts with IDH1m R/R AML have prolonged CR on single agent IVO without HSCT (22.8% of CR/CRh responders) and no pts in CR for >2 years (14% of CR/CRh responders) relapsed. A low mutational burden, lack of RTK pathway mutations and canonical AML drivers, and co-occurrence of mutations associated with clonal hematopoiesis appear to be associated with exceptional response. Clinical trial information: NCT02074839 . [Table: see text]" @default.
• W4379281501 created "2023-06-05" @default.
• W4379281501 creator A5010233223 @default.
• W4379281501 creator A5014336132 @default.
• W4379281501 creator A5048342090 @default.
• W4379281501 creator A5066934816 @default.
• W4379281501 creator A5067973814 @default.
• W4379281501 creator A5079026617 @default.
• W4379281501 date "2023-06-01" @default.
• W4379281501 modified "2023-09-25" @default.
• W4379281501 title "Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib." @default.
• W4379281501 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.7036" @default.
• W4379281501 hasPublicationYear "2023" @default.
• W4379281501 type Work @default.
• W4379281501 citedByCount "0" @default.
• W4379281501 crossrefType "journal-article" @default.
• W4379281501 hasAuthorship W4379281501A5010233223 @default.
• W4379281501 hasAuthorship W4379281501A5014336132 @default.
• W4379281501 hasAuthorship W4379281501A5048342090 @default.
• W4379281501 hasAuthorship W4379281501A5066934816 @default.
• W4379281501 hasAuthorship W4379281501A5067973814 @default.
• W4379281501 hasAuthorship W4379281501A5079026617 @default.
• W4379281501 hasConcept C104317684 @default.
• W4379281501 hasConcept C126322002 @default.
• W4379281501 hasConcept C127848430 @default.
• W4379281501 hasConcept C143065580 @default.
• W4379281501 hasConcept C185592680 @default.
• W4379281501 hasConcept C197934379 @default.
• W4379281501 hasConcept C2776694085 @default.
• W4379281501 hasConcept C3019096185 @default.
• W4379281501 hasConcept C55493867 @default.
• W4379281501 hasConcept C71924100 @default.
• W4379281501 hasConcept C72563966 @default.
• W4379281501 hasConcept C90924648 @default.
• W4379281501 hasConceptScore W4379281501C104317684 @default.
• W4379281501 hasConceptScore W4379281501C126322002 @default.
• W4379281501 hasConceptScore W4379281501C127848430 @default.
• W4379281501 hasConceptScore W4379281501C143065580 @default.
• W4379281501 hasConceptScore W4379281501C185592680 @default.
• W4379281501 hasConceptScore W4379281501C197934379 @default.
• W4379281501 hasConceptScore W4379281501C2776694085 @default.
• W4379281501 hasConceptScore W4379281501C3019096185 @default.
• W4379281501 hasConceptScore W4379281501C55493867 @default.
• W4379281501 hasConceptScore W4379281501C71924100 @default.
• W4379281501 hasConceptScore W4379281501C72563966 @default.
• W4379281501 hasConceptScore W4379281501C90924648 @default.
• W4379281501 hasFunder F4320316629 @default.
• W4379281501 hasFunder F4320336093 @default.
• W4379281501 hasIssue "16_suppl" @default.
• W4379281501 hasLocation W43792815011 @default.
• W4379281501 hasOpenAccess W4379281501 @default.
• W4379281501 hasPrimaryLocation W43792815011 @default.
• W4379281501 hasRelatedWork W2071535500 @default.
• W4379281501 hasRelatedWork W2315085516 @default.
• W4379281501 hasRelatedWork W2316407790 @default.
• W4379281501 hasRelatedWork W2374781999 @default.
• W4379281501 hasRelatedWork W2527805684 @default.
• W4379281501 hasRelatedWork W2603773853 @default.
• W4379281501 hasRelatedWork W2952239533 @default.
• W4379281501 hasRelatedWork W2964295425 @default.
• W4379281501 hasRelatedWork W2999832097 @default.
• W4379281501 hasRelatedWork W3095230966 @default.
• W4379281501 hasVolume "41" @default.
• W4379281501 isParatext "false" @default.
• W4379281501 isRetracted "false" @default.
• W4379281501 workType "article" @default.